Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

4.28USD
24 Jul 2017
Change (% chg)

$0.02 (+0.47%)
Prev Close
$4.26
Open
$4.25
Day's High
$4.33
Day's Low
$4.18
Volume
2,580,257
Avg. Vol
5,317,013
52-wk High
$7.15
52-wk Low
$3.34

Select another date:

Wed, May 10 2017

BRIEF-Synergy Pharmaceuticals reports Q1 sales $100,000

* Synergy Pharmaceuticals reports first quarter 2017 financial results and business update

BRIEF-Synergy Pharmaceuticals says to present positive TRULANCE phase 3 data

* TRULANCE 3 mg,6 mg doses showed statistical significance in percent of patients who were overall responders compared to placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Synergy Pharmaceuticals appoints Gary Gemignani as chief financial officer

* Synergy Pharmaceuticals appoints Gary G. Gemignani as chief financial officer

BRIEF-Synergy Pharmaceuticals announces issuance of three new patents expected to extend Trulance patent protection until 2032

* Announces issuance of three new patents expected to extend Trulance (Plecanatide) patent protection until 2032

BRIEF-Synergy Pharmaceuticals reports qtrly net loss per common share $0.31

* Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update

BRIEF-Synergy Pharmaceuticals provides update on phase 3 data results for Trulance

* Pivotal phase 3 data results for Trulance(Tm) (plecanatide) in the treatment of chronic idiopathic constipation (CIC) published in American Journal Of Gastroenterology

Select another date: